The Bosch Vivalytic Noro-, Rotavirus, C. diff test uses qualitative real-time PCR to detect:
- Rotavirus Type A
- Clostridioides difficile tcdA/tcdB
from soft or liquid stool samples, with results available in approximately 60 minutes.
For hospitals and laboratories considering gastrointestinal molecular diagnostics, this makes the assay not only rapid, but also investigates viral and bacterial causes of gastroenteritis within a single molecular testing workflow.
Why Can Gastroenteritis Be Difficult to Diagnose From Symptoms Alone?
Gastroenteritis generally refers to inflammation affecting the stomach and intestines and can produce symptoms including diarrhoea, vomiting, abdominal discomfort and sometimes fever.
However, the clinical syndrome can have many causes.
Bosch notes that infectious gastroenteritis is frequently caused by viruses such as Norovirus and Rotavirus, while bacterial pathogens such as C. difficile also play an important role.
This creates a problem in diagnostics.
The patient’s symptoms can indicate what type of illness is occurring without necessarily identifying which pathogen is responsible.
Norovirus, Rotavirus and C. difficile differ in their epidemiology, patient populations, transmission patterns and clinical implications, so a laboratory result can therefore provide information that symptoms alone cannot reliably establish.
Three Pathogens, Three Different Diagnostic Questions
One reason multiplex gastrointestinal testing can be useful is that the pathogens included in the assay represent quite different clinical situations.
| Pathogen | Why It May Matter |
|---|---|
| Norovirus GI/II | Highly contagious viral gastroenteritis; particularly important during outbreaks and in shared healthcare environments |
| Rotavirus Type A | Major cause of acute gastroenteritis, particularly among infants and young children |
| C. difficile | Important cause of antibiotic-associated diarrhoea and healthcare-associated gastrointestinal disease |
A single patient does not necessarily have an equal likelihood of carrying each pathogen.
- Age,
- clinical history,
- antibiotic exposure,
- healthcare contact,
- local epidemiology
- and outbreak circumstances all influence which diagnoses should be considered.
But where the clinical presentation leaves several possibilities open, multiplex PCR provides a way of investigating more than one molecular target within the same testing process.
Why Is Rotavirus Important?
Rotavirus is especially important in paediatric medicine.
WHO describes it as a common cause of diarrhoea among infants and children under five. Infection can begin with fever and vomiting before progressing to watery diarrhoea, potentially causing significant dehydration.
Vaccination has substantially changed the epidemiology of rotavirus in many countries.
However, vaccination has not eliminated the disease.
A large systematic review and meta-analysis examining 224 African studies conducted between 2009 and 2022 found an estimated Rotavirus prevalence of 29.8% among patients with gastroenteritis, based on data from more than 238,000 participants across studies from 39 African countries.
Among children under five, the pooled estimate was approximately 30.8%.
The researchers also found that prevalence was lower in studies conducted after vaccine introduction than in the pre-vaccination period, supporting the benefit of vaccination while demonstrating that Rotavirus remains relevant.
These figures should not be interpreted as the expected prevalence within every African hospital.
The studies showed considerable heterogeneity.
Nevertheless, they demonstrate why Rotavirus remains an important diagnostic consideration when children present with acute gastroenteritis.
Rotavirus Remains Particularly Relevant for African Paediatric Care
The pooled prevalence was approximately 31%, followed by Norovirus at around 15%.
Again, pooled studies should not be treated as a substitute for local surveillance.
But they illustrate an important point:
gastroenteritis in African children can have multiple viral causes, and laboratory testing can help determine which pathogens are actually circulating.
This becomes particularly relevant when hospitals are evaluating whether gastrointestinal molecular diagnostics should form part of their paediatric laboratory capacity.
What Is Multiplex Gastrointestinal PCR Testing?
PCR (polymerase chain reaction) detects specific genetic material associated with pathogens.
A conventional single-target molecular assay may investigate one organism.
- A multiplex PCR test investigates several genetic targets within the same testing process.
For the Vivalytic gastrointestinal multiplex assay, the relevant targets represent:
Norovirus;
Rotavirus;
and toxigenic C. difficile.
This allows the laboratory to ask several questions simultaneously rather than selecting one pathogen before the molecular test begins.
However, multiplex testing should not be interpreted as:
“Test every patient for everything.”
The decision to use a multiplex gastrointestinal assay should still be guided by clinical presentation, patient characteristics, local diagnostic protocols and epidemiological circumstances.
What Does the Vivalytic Gastrointestinal Multiplex Test Detect?
The Vivalytic Noro-, Rotavirus, C. diff assay uses qualitative real-time PCR.
It detects:
| Target | Detected Organism |
|---|---|
| Norovirus GI/II | Norovirus genogroup I and II |
| Rotavirus Type A | Rotavirus A |
| tcdA/tcdB | Toxigenic Clostridioides difficile |
The assay uses soft or liquid stool specimens and has an approximate 60-minute time-to-result.
Bosch describes it as a fully automated molecular test requiring only a few steps between sample and result.
Vivalytic Noro-, Rotavirus and C. Diff Test Specifications
| Specification | Vivalytic Noro-, Rotavirus, C. diff |
|---|---|
| Detectable Pathogens | Norovirus GI/II; Rotavirus Type A; C. difficile tcdA/tcdB |
| Detection Method | Qualitative real-time PCR |
| Sample Material | Soft or liquid stool |
| Time-to-Result | Approx. 60 minutes |
| Field of Application | Symptomatic patients |
| Intended Setting | Professional and laboratory use |
| Sample Volume | 300 μL per test |
| Transport Medium | 2 ml eNAT® (Copan) with regular FLOQSwabs® |
Healthcare professionals can review the manufacturer’s official Vivalytic Noro-, Rotavirus and C. diff test information.
Why Can Multiplex Testing Be Useful?
The strongest argument for multiplex diagnostics is not simply convenience.
- It is the ability to investigate different plausible causes of a clinical syndrome within one workflow.
Imagine a hospital laboratory receiving a stool sample from a patient with acute gastroenteritis.
Without further information, several causes could be considered. A sequential testing strategy might involve:
- first testing one pathogen;
- waiting for the result;
- then deciding whether another test is necessary.
A multiplex approach investigates several defined targets simultaneously.
This could potentially reduce the time required to obtain relevant pathogen information when more than one diagnosis is clinically plausible.
Multiplex PCR Does Not Remove the Need for Clinical Interpretation
This point is particularly important for gastrointestinal diagnostics.
PCR is highly sensitive.
That is generally an advantage, but sensitivity can create challenges when organisms or genetic targets are present without necessarily being the cause of the patient’s current illness.
- This is especially important with C. difficile.
Detecting tcdA/tcdB-related genetic material indicates the presence of toxigenic C. difficile targets.
It does not independently establish that the organism is responsible for every episode of diarrhoea in which the target is detected.
Patient symptoms, antibiotic exposure, specimen quality, diagnostic criteria and local laboratory algorithms still matter.
Multiplex PCR should therefore be considered a diagnostic tool providing molecular information, not an automated clinical diagnosis.
Targeted PCR or Multiplex PCR: Which Is Better?
Bosch provides both targeted gastrointestinal assays and the combined multiplex test.
- That means a laboratory does not necessarily need to approach every gastrointestinal specimen in exactly the same way.
A targeted assay may be more suitable where there is a very specific clinical question.
For example, during a well-defined suspected Norovirus outbreak, a targeted Norovirus assay may provide the information required.
Likewise, an appropriate patient with significant antibiotic-associated diarrhoea may be investigated specifically for C. difficile according to local protocols.
But where several pathogens are plausible, a multiplex assay may offer more useful diagnostic information.
So the better question is therefore not:
“Is multiplex always better?”
It is:
“Which testing strategy best answers the clinical question in front of us?”
Multiplex Testing Can Also Generate Better Local Diagnostic Data
There is another potential benefit.
A laboratory routinely testing several gastrointestinal pathogens begins generating its own dataset.
Over time, appropriately collected and analysed laboratory data may reveal:
- which pathogens occur most frequently;
- which age groups are most affected;
- whether particular pathogens peak at certain times;
- whether outbreaks are occurring;
- and how diagnostic demand changes.
This can become valuable for laboratory planning.
Instead of relying entirely on international prevalence estimates, the healthcare organisation begins to understand its own patient population.
That is especially important across Africa, where published epidemiological evidence remains uneven between countries and regions.
What About Rotavirus Vaccination?
Rotavirus vaccination remains a central prevention strategy, as diagnostic testing does not replace vaccination.
They address different parts of disease management.
- Vaccination aims to prevent severe disease from happening in the first place
- Diagnostic testing helps determine whether Rotavirus is responsible when a patient presents with gastroenteritis.
The African meta-analysis mentioned above, found lower pooled Rotavirus prevalence in studies conducted after vaccine introduction compared with the pre-vaccination era, reinforcing the importance of vaccination.
Nevertheless, Rotavirus continued to be detected after vaccine introduction.
For paediatric hospitals and laboratories, diagnostic capability may therefore remain relevant even in countries with established vaccination programmes.
Questions Laboratory Managers Should Consider
Before introducing multiplex gastrointestinal PCR testing, healthcare organisations should consider:
- Which gastrointestinal pathogens do we currently test for?
- Which patient populations generate the greatest testing demand?
- How often are Norovirus, Rotavirus and C. difficile clinically suspected?
- Do samples currently leave the facility for molecular testing?
- What is our current sample-to-result turnaround time?
- When would a targeted test be preferable to a multiplex panel?
- How would C. difficile PCR results be interpreted within our diagnostic algorithm?
- How frequently do we investigate gastrointestinal outbreaks?
- Would faster results meaningfully change patient-management or infection-control decisions?
- Do we already have molecular diagnostic infrastructure?
- What training would laboratory staff require?
- How reliably can cartridges and compatible specimen materials be supplied?
- What technical and after-sales support is available?
- Which other Vivalytic molecular assays could our facility realistically use?
These are the questions that should drive procurement—not simply how many pathogens appear on the cartridge.
Is Your Laboratory Considering Multiplex Gastrointestinal PCR Testing?
If your hospital, diagnostic laboratory, clinic or healthcare organisation is reviewing its gastrointestinal testing or wider molecular diagnostic capabilities, MediDiagAfrica can provide further information about the Bosch Vivalytic platform and the Vivalytic Noro-, Rotavirus, C. diff assay.
The discussion can start with your existing diagnostic workflow:
- Which gastrointestinal pathogens do you currently investigate?
- Are your samples processed locally or referred elsewhere?
- How quickly are results currently available?
- Would targeted or multiplex PCR better suit your patient population?
- Could the same Vivalytic platform support other molecular testing requirements within your organisation?
From there, you can:
Request information about the Vivalytic Noro-, Rotavirus, C. diff test
Request a Vivalytic demonstration
Discuss your laboratory’s gastrointestinal diagnostic requirements
Enquire about Vivalytic availability in your African country
Individual Vivalytic products are not necessarily available in every market, so test availability should be confirmed for the relevant country before procurement.
This article is intended for healthcare and laboratory professionals and provides general diagnostic and product information. It should not replace clinical guidelines, professional medical judgement, local diagnostic algorithms, infection-control protocols or applicable regulatory requirements.